Recent blog posts
GPCR Targets and Pipeline at the JP Morgan Healthcare Conference 2024 (5)
GPCR Targets and Pipeline at the JP Morgan Healthcare Conference 2024 (5)
21 March 2024
In this article, we will focus on Sosei Heptares, a leading company in the field of GPCR new drug development, and its GPCR research and development pipeline.
Read →
GPCR Targets and Pipeline at the JP Morgan Healthcare Conference 2024 (4)
GPCR Targets and Pipeline at the JP Morgan Healthcare Conference 2024 (4)
21 March 2024
This piece will highlight GPCR targets and notable pipelines from Chugai, UCB, Ascendis, and BridgeBio at the 2024 JP Morgan Healthcare Conference.
Read →
GPCR Targets and Pipeline at the JP Morgan Healthcare Conference 2024 (3)
GPCR Targets and Pipeline at the JP Morgan Healthcare Conference 2024 (3)
21 March 2024
The article will discuss GPCR targets and noteworthy pipelines from Roche and TEVA at JPM Healthcare 2024.
Read →
GPCR Targets and Pipeline at the JP Morgan Healthcare Conference 2024 (2)
GPCR Targets and Pipeline at the JP Morgan Healthcare Conference 2024 (2)
21 March 2024
This article summarizes GPCR targets and pipelines highlighted by AstraZeneca, Pfizer, and Eli Lilly at JP Morgan Healthcare Conference 2024.
Read →
GPCR Targets and Pipeline at the JP Morgan Healthcare Conference 2024 (1)
GPCR Targets and Pipeline at the JP Morgan Healthcare Conference 2024 (1)
20 March 2024
This article will introduce the GPCR targets and pipelines that received attention at the JP Morgan Healthcare Conference 2024.
Read →
Erdafitinib: A Quick Look at Its R&D Progress and Clinical Results from the 2024 ASCO_GU
Erdafitinib: A Quick Look at Its R&D Progress and Clinical Results from the 2024 ASCO_GU
29 February 2024
TAR-210 is an intravesical drug delivery system that is designed to provide local, continuous release of erdafitinib.
Read →
An analysis of Enzalutamide's R&D progress and its clinical results presented at the 2024 ASCO_GU Annual Meeting
An analysis of Enzalutamide's R&D progress and its clinical results presented at the 2024 ASCO_GU Annual Meeting
29 February 2024
On Jan 25, 2024, the 2024 ASCO_GU reported results from suspending enzalutamide combo tx in high-risk BCR prostate cancer men.
Read →
Decoding Darolutamide: a comprehensive study of its R&D trends and its clinical results in 2024 ASCO_GU
Decoding Darolutamide: a comprehensive study of its R&D trends and its clinical results in 2024 ASCO_GU
27 February 2024
Hospitalization data for darolutamide/docetaxel in metastatic prostate cancer were presented at 2024 ASCO_GU on Jan 25, comparing daro/docetaxel/ADT with placebo/docetaxel/ADT.
Read →
Exploring Nivolumab's R&D successes and its clinical results at the 2024 ASCO_GU
Exploring Nivolumab's R&D successes and its clinical results at the 2024 ASCO_GU
27 February 2024
On Jan 25, 2024, new data comparing subcutaneous (SC) versus intravenous (IV) nivolumab in pre-treated advanced/metastatic ccRCC was unveiled at ASCO_GU 2024.
Read →
Nitroxoline: A Quick Look at Its R&D Progress and Clinical Results from the 2024 ASCO_GU
Nitroxoline: A Quick Look at Its R&D Progress and Clinical Results from the 2024 ASCO_GU
23 February 2024
APL-1202 (nitroxoline) is a reversible and orally available MetAP2 inhibitor with anti-angiogenic and anti-tumor activities.
Read →
An analysis of Mitomycin's R&D progress and its clinical results presented at the 2024 ASCO_GU Annual Meeting
An analysis of Mitomycin's R&D progress and its clinical results presented at the 2024 ASCO_GU Annual Meeting
23 February 2024
On Jan 25, 2024, the 2024 ASCO_GU summarized a phase III trial on first-time bladder cancer patients treated with neoadjuvant intravesical MMC.
Read →
Decoding Infigratinib: a comprehensive study of its R&D trends and its clinical results in 2024 ASCO_GU
Decoding Infigratinib: a comprehensive study of its R&D trends and its clinical results in 2024 ASCO_GU
23 February 2024
2024 ASCO_GU presented new trial data on infigratinib, an FGFR3 inhibitor, showing promise in clinical use.
Read →